SMS Pharmaceuticals Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/l2n4dkxigyz7m3t1dx8mdj97.pdf

Key Takeaways


Profitability Turnaround

Potluri: "May be, it might take 1-2 quarters but again as we mentioned, the companies is on the bounce back mode."

Anti-Diabetic: The New Anchor

Potluri: "We are an API Company, definitely based on the current trend we think the anti-diabetic could be the driving force in the next year as well because of the recent expiry on that sitagliptin but it could definitely change."

Ibuprofen: Pricing Floor & Regulatory Catalyst

Potluri: "We feel that the prices have bottomed out at this point of time and we feel that unless there is a new entrant or someone is having some issues with manufacturing. I think the prices will more or less be the same, unless something is happening in the market so that we keep our eyes open and we are watchful but we cannot predict those at this point of time."

ARV: From Headwind to Tailwind

Potluri: "Anti-viral will come back, definitely we will be and that will be additional revenue for the Company."

Portfolio & Operational Strategy

Potluri: "We want to consolidate at this point of time before going for another expansion."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin normalizationReach normalized level of 18%-20%Next 1-2 quarters
Ibuprofen Europe sales uptickSee a very good uptick in sales to EuropeNext 4-6 months
Ibuprofen capacity expansionScale to 700 tons/month (₹10-15 cr CAPEX)Operational by Q3 FY24
Ibuprofen FY24 revenue contribution~25% of total revenue (~₹150-200 crores)FY24
ARV revenue contributionReturn to 12%-15% of revenue, but not very sure because it is based purely on tendersNext year (FY24)
Backward integrationAchieve 80%-85% in-house raw material manufacturing, currently around 50%FY24
Domestic revenue shareIncrease from 18% to 25%-30%Going forward
Capacity utilization (ex-ibuprofen)Reach at least 60% from current 40%No date
R&D spendSteady-state at 3%-4% of revenueOngoing

Key Metrics

MetricQ3 FY23
Revenue from operations (API segment)₹146.2 cr, API segment contributed ~98.2% of consolidated revenue
9M FY23 revenue from operations (API segment)₹368.7 cr, API segment contributed ~99% of consolidated revenue
EBITDA margin13.9%, improved 504 bps sequentially
Profit after tax₹5.3 cr, substantial growth from previous quarter
Normalized EBITDA margin target18%–20%, expected in the next couple of quarters
Revenue growth expectation (not formal target)15%–20% on existing revenues, typical range
API domestic market share15% of API revenue, expected to increase to 25%–30%
API export market share85% of API revenue
Top 3 export geographies contribution65%–70% of export revenue, from US, Europe, and Japan
Anti-diabetic therapy share of revenue41% of total revenue from operations
ARV therapy share of revenue1% of total sales, down from ~30%–40% last year
Anti-migraine therapy share of revenue14% of total sales, expected to go up to 15%
Ibuprofen current monthly production180–200 tons, with installed capacity of 300–400 tons per month
Ibuprofen capacity utilization60%–70%
Overall capacity utilization (ex-ibuprofen)40%, target to hit at least 60%
R&D spend (9M FY23)~3% of revenue, steady-state target 3%–4%
CAPEX done so far this year₹5–8 cr, for regular environmental and balance equipment
Backward integration level~50%, target 80%–85% in FY24
Nine-month inventory reduction15%–20% lower compared to FY2022